Founded to Serve Health: Contributing to a Sustainable World – Servier
Servier shared a post on LinkedIn:
“Founded to serve health, at Servier, we aspire to create meaningful social impact for patients and contribute to a sustainable world.
Our unique governance — led by the non-profit foundation — allows us to reinvest close to 20% of revenue from brand-name medicines in R and D each year. This commitment accelerates the discovery of new treatments across our therapeutic areas: oncology, cardiometabolism and venous diseases, and neurology.
Proud to be the 35th largest pharmaceutical group worldwide and the 2nd largest in France, we continue to innovate with 29 brand-name medicines distributed globally.
With over 22,000 dedicated employees, our medicines reach patients in close to 140 countries, reflecting our expertise and passion for improving lives. Our 2030 strategy aligns with today’s health challenges, including the growing prevalence of cancer and the global impact of cardiometabolic diseases.
Learn more about Servier.”
More posts featuring Servier Pharmaceuticals.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023